Bajaj Healthcare Limited
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, … Read more
Bajaj Healthcare Limited (BAJAJHCARE) - Net Assets
Latest net assets as of September 2025: ₹4.86 Billion INR
Based on the latest financial reports, Bajaj Healthcare Limited (BAJAJHCARE) has net assets worth ₹4.86 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹8.39 Billion) and total liabilities (₹3.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹4.86 Billion |
| % of Total Assets | 57.98% |
| Annual Growth Rate | 21.65% |
| 5-Year Change | 80.4% |
| 10-Year Change | 425.95% |
| Growth Volatility | 36.8 |
Bajaj Healthcare Limited - Net Assets Trend (2011–2025)
This chart illustrates how Bajaj Healthcare Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bajaj Healthcare Limited (2011–2025)
The table below shows the annual net assets of Bajaj Healthcare Limited from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹4.66 Billion | +67.47% |
| 2024-03-31 | ₹2.78 Billion | -24.29% |
| 2023-03-31 | ₹3.68 Billion | +11.93% |
| 2022-03-31 | ₹3.28 Billion | +27.12% |
| 2021-03-31 | ₹2.58 Billion | +70.45% |
| 2020-03-31 | ₹1.52 Billion | +17.43% |
| 2019-03-31 | ₹1.29 Billion | +13.64% |
| 2018-03-31 | ₹1.14 Billion | +14.76% |
| 2017-03-31 | ₹990.00 Million | +11.70% |
| 2016-03-31 | ₹886.32 Million | +126.85% |
| 2015-03-31 | ₹390.72 Million | +23.81% |
| 2014-03-31 | ₹315.57 Million | +6.66% |
| 2013-03-31 | ₹295.85 Million | -3.45% |
| 2012-03-31 | ₹306.41 Million | +2.17% |
| 2011-03-31 | ₹299.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bajaj Healthcare Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1528.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹3.04 Billion | 65.24% |
| Common Stock | ₹157.92 Million | 3.39% |
| Other Comprehensive Income | ₹161.21 Million | 3.46% |
| Other Components | ₹1.30 Billion | 27.92% |
| Total Equity | ₹4.66 Billion | 100.00% |
Bajaj Healthcare Limited Competitors by Market Cap
The table below lists competitors of Bajaj Healthcare Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Etteplan Oyj
HE:ETTE
|
$40.49 Million |
|
International Meal Company Alimentação S.A
SA:MEAL3
|
$40.49 Million |
|
PAMT CORP
NASDAQ:PAMT
|
$40.51 Million |
|
DLP Resources Inc
OTCQB:DLPRF
|
$40.52 Million |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
$40.48 Million |
|
ICC Holdings Inc
NASDAQ:ICCH
|
$40.47 Million |
|
Vistin Pharma ASA
OL:VISTN
|
$40.47 Million |
|
Ardea Resources Ltd
AU:ARL
|
$40.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bajaj Healthcare Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,783,609,000 to 4,661,642,000, a change of 1,878,033,000 (67.5%).
- Net income of 394,955,000 contributed positively to equity growth.
- Dividend payments of 27,598,000 reduced retained earnings.
- New share issuances of 1,496,975,000 increased equity.
- Other comprehensive income increased equity by 189,410,999.
- Other factors decreased equity by 175,709,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹394.95 Million | +8.47% |
| Dividends Paid | ₹27.60 Million | -0.59% |
| Share Issuances | ₹1.50 Billion | +32.11% |
| Other Comprehensive Income | ₹189.41 Million | +4.06% |
| Other Changes | ₹-175.71 Million | -3.77% |
| Total Change | ₹- | 67.47% |
Book Value vs Market Value Analysis
This analysis compares Bajaj Healthcare Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.26x to 2.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | ₹11.11 | ₹313.90 | x |
| 2012-03-31 | ₹11.35 | ₹313.90 | x |
| 2013-03-31 | ₹10.96 | ₹313.90 | x |
| 2014-03-31 | ₹11.69 | ₹313.90 | x |
| 2015-03-31 | ₹14.47 | ₹313.90 | x |
| 2016-03-31 | ₹32.83 | ₹313.90 | x |
| 2017-03-31 | ₹35.95 | ₹313.90 | x |
| 2018-03-31 | ₹41.17 | ₹313.90 | x |
| 2019-03-31 | ₹46.78 | ₹313.90 | x |
| 2020-03-31 | ₹54.93 | ₹313.90 | x |
| 2021-03-31 | ₹93.63 | ₹313.90 | x |
| 2022-03-31 | ₹119.02 | ₹313.90 | x |
| 2023-03-31 | ₹133.23 | ₹313.90 | x |
| 2024-03-31 | ₹100.86 | ₹313.90 | x |
| 2025-03-31 | ₹144.77 | ₹313.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bajaj Healthcare Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.47%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.28%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.79x
- Recent ROE (8.47%) is below the historical average (9.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.91% | 3.73% | 1.16x | 3.45x | ₹14.74 Million |
| 2012 | 2.12% | 0.46% | 1.16x | 3.96x | ₹-24.14 Million |
| 2013 | -3.57% | -0.62% | 1.30x | 4.43x | ₹-40.14 Million |
| 2014 | 6.25% | 0.96% | 1.41x | 4.61x | ₹-11.84 Million |
| 2015 | 19.23% | 3.44% | 1.50x | 3.73x | ₹36.08 Million |
| 2016 | 9.25% | 3.68% | 1.07x | 2.36x | ₹-6.63 Million |
| 2017 | 7.90% | 3.39% | 1.05x | 2.21x | ₹-20.75 Million |
| 2018 | 13.37% | 5.29% | 1.07x | 2.36x | ₹38.25 Million |
| 2019 | 12.63% | 5.05% | 1.21x | 2.07x | ₹34.00 Million |
| 2020 | 16.65% | 7.02% | 1.10x | 2.15x | ₹100.76 Million |
| 2021 | 32.16% | 12.67% | 1.25x | 2.03x | ₹572.68 Million |
| 2022 | 21.73% | 10.51% | 0.94x | 2.20x | ₹385.37 Million |
| 2023 | 11.70% | 6.66% | 0.72x | 2.45x | ₹62.55 Million |
| 2024 | -30.10% | -17.70% | 0.62x | 2.75x | ₹-1.12 Billion |
| 2025 | 8.47% | 7.28% | 0.65x | 1.79x | ₹-71.21 Million |
Industry Comparison
This section compares Bajaj Healthcare Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $11,607,517,057
- Average return on equity (ROE) among peers: 18.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bajaj Healthcare Limited (BAJAJHCARE) | ₹4.86 Billion | 14.91% | 0.72x | $40.48 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $923.46 Million | 6.27% | 1.10x | $10.43 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $3.57 Billion | 19.23% | 2.08x | $152.84 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.58 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.39 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $131.79 Million |
| Albert David Limited (ALBERTDAVD) | $755.53 Million | 10.10% | 1.68x | $15.35 Million |
| Alivus Life Sciences Limited (ALIVUS) | $7.53 Billion | 46.71% | 1.65x | $350.45 Million |
| Alkem Laboratories Limited (ALKEM) | $12.05 Billion | 19.50% | 0.29x | $2.46 Billion |
| Alpa Laboratories Limited (ALPA) | $865.59 Million | -1.61% | 0.48x | $5.26 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.75 Million |